Page 83 - Drug Class Review
P. 83
Drug Effectiveness Review Project
• Withdrawals for any reason before the end of treatment show that there are no significant differences between withdrawals in the 1-4 mg/d RIV group and placebo group at 12 and 26 weeks; there are significant differences for the 6-12 mg/d group in favor of placebo at 12, 18 and 26 weeks; (20/133 vs. 8/133, 16/45 vs. 2/24, 367/1052 vs. 145/868; OR 2.60; 95% CI: 1.19 – 5.68; OR 4.02; 95% CI: 1.31 – 12.32; OR 2.40; 95% CI: 1.95 – 2.96) Withdrawals by week 26 for adverse events showed no significant differences between the 1-4 mg/d • RIV and placebo groups (55/645 vs. 54/646; OR 1.01;
Final Report Update 1 Authors: Birks et al. Year: 2004 ADVERSE EVENTS: Alzheimer's Drugs
